{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:04:26Z","timestamp":1761102266434},"reference-count":24,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5582\/irdr.2017.01036","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T22:14:01Z","timestamp":1503094441000},"page":"183-190","source":"Crossref","is-referenced-by-count":10,"title":["Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study"],"prefix":"10.5582","volume":"6","author":[{"given":"Jos\u00e9 Francisco da Silva","family":"Franco","sequence":"first","affiliation":[{"name":"Pediatric Department, Catholic University - PUC"},{"name":"Nuclear and Energy Research Institute (IPEN\/USP)"},{"name":"Genetics Unit of the Pediatrics Department, Children's Institute, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"El Dib","sequence":"additional","affiliation":[{"name":"Institute of Science and Technology, Department of Biosciences and Oral Diagnosis, Unesp - Univ Estadual Paulista"},{"name":"McMaster Institute of Urology, McMaster University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University"},{"name":"School of Medicine, University of Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Soares","sequence":"additional","affiliation":[{"name":"Genetics Unit of the Pediatrics Department, Children's Institute, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noala Vicensoto Moreira","family":"Milhan","sequence":"additional","affiliation":[{"name":"Institute of Science and Technology, Department of Biosciences and Oral Diagnosis, Unesp - Univ Estadual Paulista"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian Maria Jos\u00e9","family":"Albano","sequence":"additional","affiliation":[{"name":"Genetics Unit of the Pediatrics Department, Children's Institute, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Ae","family":"Kim","sequence":"additional","affiliation":[{"name":"Genetics Unit of the Pediatrics Department, Children's Institute, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Neufield E, Muenzer J. The mucopolysaccharidoses. In: The metabolic and molecular bases of inherited disease (Scriver C, Beaudet A, Valle D, Sly W, eds). The McGraw-Hill Companies, New York, USA, 2001, pp.3421-52."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2016; 4:CD009354.","DOI":"10.1002\/14651858.CD009354.pub4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tomanin R, Zanetti A, D'Avanzo F, Rampazzo A, Gasparotto N, Parini R, Pascarella A, Concolino D, Procopio E, Fiumara A, Borgo A, Frigo AC, Scarpa M. Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014; 9:129.","DOI":"10.1186\/s13023-014-0129-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Brunelli MJ, Atallah AN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopoly-saccharidosis type VI. Cochrane database Syst Rev. 2016; 3:CD009806.","DOI":"10.1002\/14651858.CD009806.pub2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007; 120:405-418.","DOI":"10.1542\/peds.2006-2184"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, Kaplan P, Simon J, Butensky E, Hopwood JJ. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004; 144:574-580.","DOI":"10.1016\/j.jpeds.2004.03.018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, Fallet S. The natural history of MPS I: Global perspectives from the MPS I Registry. Genet Med. 2014; 16:759-765.","DOI":"10.1038\/gim.2014.25"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N, Sciarappa K, Barbier AJ. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016; 18:73-81.","DOI":"10.1038\/gim.2015.36"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nowaczyk MJ, Clarke JT, Morin JD. Glaucoma as an early complication of Hurler's disease. Arch Dis Child. 1988; 63:1091-1093.","DOI":"10.1136\/adc.63.9.1091"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DYJ, Shapiro E, Thomas J, Viskochil D, Wraith JE. The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007; 91:37-47.","DOI":"10.1016\/j.ymgme.2007.01.011"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, Kakkis ED, Guffon N. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007; 120:e37-46.","DOI":"10.1542\/peds.2006-2156"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010; 5:5.","DOI":"10.1186\/1750-1172-5-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Muenzer J. The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004; 144:S27-34.","DOI":"10.1016\/j.jpeds.2004.01.052"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Giugliani R, Federhen A, Mu\u00f1oz Rojas MV, et al. Terapia de reposi\u00e7\u00e3o enzim\u00e1tica para as mucopolissacaridoses I, II e VI: Recomenda\u00e7\u00f5es de um grupo de especialistas brasileiros. Rev Assoc Med Bras. 2010; 56:271-7.","DOI":"10.1590\/S0104-42302010000300009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Le\u00e3o Teles E, Valayannopoulos V, CSP Stdudy Group. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. 2013; 36:373-384.","DOI":"10.1007\/s10545-011-9410-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Froissart R, Da Silva IM, Maire I. Mucopolysaccharidosis type II: An update on mutation spectrum. Acta Paediatr. 2007; 96:71-77.","DOI":"10.1111\/j.1651-2227.2007.00213.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, Vellodi A, Wraith JE. Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey. Genet Med. 2011; 13:102-109.","DOI":"10.1097\/GIM.0b013e318206786f"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004; 144:581-588.","DOI":"10.1016\/j.jpeds.2004.01.046"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014; 111:63-72.","DOI":"10.1016\/j.ymgme.2013.11.015"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L, Norato DY, Brum JM, Beesley C, Winchester B, Giugliani R, Hopwood JJ. Identification and characterization of 13 new mutations in mucopoly-saccharidosis type I patients. Mol Genet Metab. 2003; 78:37-43.","DOI":"10.1016\/S1096-7192(02)00200-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hopwood JJ, Bunge S, Morris CP, Wilson PJ, Steglich C, Beck M, Schwinger E, Gal A. Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase gene. Hum Mutat. 1993; 2:435-442.","DOI":"10.1002\/humu.1380020603"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Karageorgos L, Brooks DA, Pollard A, et al. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat. 2007; 28:897-903.","DOI":"10.1002\/humu.20534"},{"key":"23","unstructured":"23. Leal GN. Echocardiographic study of pediatric patients with mucopolysaccharidosis (dissertation). S\u00e3o Paulo: University of S\u00e3o Paulo, Faculty of Medicine; 2009. http:\/\/www.teses.usp.br\/teses\/disponiveis\/5\/5141\/tde-08122009-172753\/pt-br.php (accessed August 02, 2017)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Dornelles AD, de Camargo Pinto LL, de Paula AC, et al. Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network. Genet Mol Biol. 2014; 37:23-29.","DOI":"10.1590\/S1415-47572014000100006"}],"container-title":["Intractable & Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/6\/3\/6_2017.01036\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:43:12Z","timestamp":1570030992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/6\/3\/6_2017.01036\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2017.01036","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}